{"id":65332,"date":"2026-05-14T20:06:15","date_gmt":"2026-05-14T12:06:15","guid":{"rendered":"https:\/\/flcube.com\/?p=65332"},"modified":"2026-05-14T20:06:17","modified_gmt":"2026-05-14T12:06:17","slug":"henlius-biotech-secures-australian-tga-approval-for-hlx48-phase-i-trial-novel-egfr-c-met-bispecific-adc-targets-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65332","title":{"rendered":"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced it has received <strong>regulatory approval from Australia&#8217;s Therapeutic Goods Administration (TGA)<\/strong> to initiate a <strong>Phase I clinical trial<\/strong> for its pipeline candidate <strong>HLX48<\/strong>, an <strong>EGFR\/c-Met bispecific antibody-drug conjugate (ADC)<\/strong>. The <strong>first-in-human (FIH) study<\/strong> will evaluate the molecule in patients with <strong>advanced\/metastatic solid tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-clinical-development-framework\">Regulatory Milestone &amp; Clinical Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Henlius Biotech Inc. (HKG: 2696)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>Therapeutic Goods Administration (TGA), Australia<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase I (First-in-Human)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced\/metastatic solid tumors<\/td><\/tr><tr><td><strong>Geographic Strategy<\/strong><\/td><td>Australia as international development hub<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Early clinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-dual-targeting-mechanism-of-action\">Drug Profile &amp; Dual-Targeting Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>EGFR\/c-Met bispecific antibody-drug conjugate (ADC)<\/strong><\/li>\n\n\n\n<li><strong>Dual Binding:<\/strong> Simultaneously binds with <strong>high affinity to EGFR and c-Met<\/strong> on tumor cell surfaces<\/li>\n\n\n\n<li><strong>Ligand Blockade:<\/strong> Prevents interaction with <strong>epidermal growth factor (EGF)<\/strong> and <strong>hepatocyte growth factor (HGF)<\/strong><\/li>\n\n\n\n<li><strong>Synergistic Inhibition:<\/strong> Blocks two key tumor growth and survival signaling pathways at the source<\/li>\n\n\n\n<li><strong>Resistance Overcoming:<\/strong> Potential to address <strong>EGFR-targeted therapy resistance<\/strong> caused by mechanisms like <strong>MET amplification<\/strong><\/li>\n\n\n\n<li><strong>Preclinical Evidence:<\/strong> Demonstrated <strong>significant anti-tumor activity<\/strong> across multiple tumor models<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-amp-competitive-differentiation\">Strategic Significance &amp; Competitive Differentiation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bispecific-adc-innovation\">Bispecific ADC Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Target Combination:<\/strong> EGFR\/c-Met dual targeting addresses complementary oncogenic pathways<\/li>\n\n\n\n<li><strong>Enhanced Specificity:<\/strong> Bispecific design potentially improves tumor selectivity over monospecific ADCs<\/li>\n\n\n\n<li><strong>Payload Delivery:<\/strong> ADC format enables targeted cytotoxic payload delivery to dual-positive tumor cells<\/li>\n\n\n\n<li><strong>Resistance Management:<\/strong> Addresses key clinical challenge of acquired resistance to EGFR inhibitors<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-international-development-strategy\">International Development Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Australia Selection:<\/strong> Leverages Australia&#8217;s efficient regulatory pathway and strong clinical trial infrastructure<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> TGA approval represents first step toward broader international development<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expands Henlius&#8217;s oncology pipeline beyond biosimilars into novel targeted therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-therapeutic-opportunity\">Market Context &amp; Therapeutic Opportunity<\/h2>\n\n\n\n<p><strong>EGFR\/c-Met Target Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EGFR Overexpression:<\/strong> Common in multiple solid tumors including lung, colorectal, and head\/neck cancers<\/li>\n\n\n\n<li><strong>c-Met Amplification:<\/strong> Emerging resistance mechanism to EGFR-targeted therapies<\/li>\n\n\n\n<li><strong>Co-expression Patterns:<\/strong> Significant patient populations exhibit dual EGFR\/c-Met positivity<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Limited effective options for patients developing resistance to current EGFR inhibitors<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Landscape:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bispecific ADC Space:<\/strong> Emerging therapeutic class with limited clinical-stage candidates<\/li>\n\n\n\n<li><strong>First-Mover Potential:<\/strong> Early clinical entry could establish significant competitive advantage<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Future opportunities for combination with other targeted therapies or immunotherapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-commercial-outlook\">Development Timeline &amp; Commercial Outlook<\/h2>\n\n\n\n<p>The Phase I trial will assess safety, tolerability, pharmacokinetics, and preliminary efficacy of HLX48. Given the strong preclinical rationale and unmet medical need in EGFR-resistant populations, successful early clinical data could position HLX48 for accelerated development pathways.<\/p>\n\n\n\n<p>Success would represent a significant milestone in Henlius&#8217;s strategic evolution from primarily biosimilars-focused company to innovative oncology drug developer with proprietary assets addressing high-value therapeutic areas.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of HLX48. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051300523_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051300523_c.\"><\/object><a id=\"wp-block-file--media-38645ab3-b9fc-4ad8-a7a5-99d55eaa3933\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051300523_c.pdf\">2026051300523_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051300523_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-38645ab3-b9fc-4ad8-a7a5-99d55eaa3933\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia&#8217;s Therapeutic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,270,862],"class_list":["post-65332","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia&#039;s Therapeutic Goods Administration (TGA) to initiate a Phase I clinical trial for its pipeline candidate HLX48, an EGFR\/c-Met bispecific antibody-drug conjugate (ADC). The first-in-human (FIH) study will evaluate the molecule in patients with advanced\/metastatic solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65332\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia&#039;s Therapeutic Goods Administration (TGA) to initiate a Phase I clinical trial for its pipeline candidate HLX48, an EGFR\/c-Met bispecific antibody-drug conjugate (ADC). The first-in-human (FIH) study will evaluate the molecule in patients with advanced\/metastatic solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65332\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T12:06:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T12:06:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65332#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65332\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\\\/c-Met Bispecific ADC Targets Advanced Solid Tumors\",\"datePublished\":\"2026-05-14T12:06:15+00:00\",\"dateModified\":\"2026-05-14T12:06:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65332\"},\"wordCount\":491,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65332#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65332\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65332\",\"name\":\"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\\\/c-Met Bispecific ADC Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T12:06:15+00:00\",\"dateModified\":\"2026-05-14T12:06:17+00:00\",\"description\":\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia's Therapeutic Goods Administration (TGA) to initiate a Phase I clinical trial for its pipeline candidate HLX48, an EGFR\\\/c-Met bispecific antibody-drug conjugate (ADC). The first-in-human (FIH) study will evaluate the molecule in patients with advanced\\\/metastatic solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65332#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65332\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65332#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\\\/c-Met Bispecific ADC Targets Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia's Therapeutic Goods Administration (TGA) to initiate a Phase I clinical trial for its pipeline candidate HLX48, an EGFR\/c-Met bispecific antibody-drug conjugate (ADC). The first-in-human (FIH) study will evaluate the molecule in patients with advanced\/metastatic solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65332","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors","og_description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia's Therapeutic Goods Administration (TGA) to initiate a Phase I clinical trial for its pipeline candidate HLX48, an EGFR\/c-Met bispecific antibody-drug conjugate (ADC). The first-in-human (FIH) study will evaluate the molecule in patients with advanced\/metastatic solid tumors.","og_url":"https:\/\/flcube.com\/?p=65332","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T12:06:15+00:00","article_modified_time":"2026-05-14T12:06:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65332#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65332"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors","datePublished":"2026-05-14T12:06:15+00:00","dateModified":"2026-05-14T12:06:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65332"},"wordCount":491,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","Henlius Biotech","HKG: 2696"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65332#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65332","url":"https:\/\/flcube.com\/?p=65332","name":"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T12:06:15+00:00","dateModified":"2026-05-14T12:06:17+00:00","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia's Therapeutic Goods Administration (TGA) to initiate a Phase I clinical trial for its pipeline candidate HLX48, an EGFR\/c-Met bispecific antibody-drug conjugate (ADC). The first-in-human (FIH) study will evaluate the molecule in patients with advanced\/metastatic solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65332#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65332"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65332#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial \u2013 Novel EGFR\/c-Met Bispecific ADC Targets Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65332"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65332\/revisions"}],"predecessor-version":[{"id":65334,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65332\/revisions\/65334"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}